Meeting
2017 Gastrointestinal Cancers Symposium
Detection of circulating tumor cells (CTC) using a non-EpCAM-based, high-definition, single-cell assay in advanced hepatocellular carcinoma (HCC) for patients enrolled on phase I and II trials of sorafenib plus temsirolimus.
Authors
Robin Kate Kelley
University of California, San Francisco, San Francisco, CA
Robin Kate Kelley , Mariam Rodriguez Lee , Jimmy Hwang , John Dozier Gordan , Halla Sayed Nimeiri , Andrea Grace Bocobo , Sheetal Mehta Kircher , Advaita Kanakamedala , Mary Frances Mulcahy , Al Bowen Benson III, Peter Kuhn , Alan P. Venook
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 311)
DOI
10.1200/JCO.2017.35.4_suppl.311
Abstract #
311
Poster Bd #
E3
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Next-generation sequencing (NGS) in an advanced hepatocellular carcinoma (HCC) cohort: Analyses of TP53 and CTNNB1.
First Author: Robin Kate Kelley
Poster
2015 Gastrointestinal Cancers Symposium
Phase II trial of temsirolimus (TEM) plus sorafenib (SOR) in hepatocellular carcinoma (HCC).
First Author: Robin Kate Kelley
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of modulation of sorafenib (SOR)-induced autophagy using hydroxychloroquine (HCQ) in advanced hepatocellular cancer (HCC): Planned interim efficacy and safety analysis.
First Author: Sukeshi Patel Arora
Poster
2019 Gastrointestinal Cancers Symposium
Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).
First Author: Bridget Keenan